Fig. 2: CUDC-907 can relatively safely inhibit the growth of MB cells by downregulating MYC. | Cell Death Discovery

Fig. 2: CUDC-907 can relatively safely inhibit the growth of MB cells by downregulating MYC.

From: The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma

Fig. 2

A Morphological images and growth curves of D283 and MB230524 were recorded after treatment of CUDC-907 for 48 h. B EdU assay was used to detect the effect of CUDC-907 on the DNA synthesis ability of MB cells. C The results of the transwell assay demonstrating the impact of CUDC-907 on the migratory capacity of D283 and MB230524 cells. D Apoptosis of MB cells treated with CUDC-907 was assessed by flow cytometry. E The expression of MYC was detected using western blot after treatment with CUDC-907 for 24 h and 48 h. F Western blot was used to detect the expression of HDAC and PI3K related proteins in the MYC upstream pathway. G Effect of CUDC-907 on proliferation rate of normal astrocyte SVG p12. H CCK8 assay was used to detect the viability of SVG p12 at the treatment endpoint. I Bright field images of cerebral organoids exposed to DMSO or 40 nM CUDC-907 for 9 days. J The 2D areas of three samples in each group were measured at 0 days, 3 days, 6 days and 9 days, and growth curves were plotted. K Results of the EdU assay in cerebral organoids. L Immunofluorescence (IF) analyses of cerebral organoids. NS p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001.

Back to article page